Analytical Data
-
Gene name
IFNL3
- Application
-
Alternative Names
IFNL3;IL28B;IL28C;ZCYTO22;Interferon lambda-3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14879
-
Expression Region
1-490aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMGSMSEVTKNSLEKILPQLKCHFTWNLFKE DSVSRDLEDRVCNQIEFLNTEFKATMYNLLAYIKHLDGNNEAALECLRQA EELIQQEHADQAEIRSLVTWGNYAWVYYHLGRLSDAQIYVDKVKQTCKKF SNPYSIEYSELDCEEGWTQLKCGRNERAKVCFEKALEEKPNNPEFSSGLA IAMYHLDNHPEKQFSTDVLKQAIELSPDNQYVKVLLGLKLQKMNKEAEGE QFVEEALEKSPCQTDVLRSAAKFYRRKGDLDKAIELFQRVLESTPNNGYL YHQIGCCYKAKVRQMQNTGESEASGNKEMIEALKQYAMDYSNKALEKGLN PLNAYSDLAEFLETECYQTPFNKEVPDAEKQQSHQRYCNLQKYNGKSEDT AVQHGLEGLSISKKSTDKEEIKDQPQNVSENLLPQNAPNYWYLQGLIHKQ NGDLLQAAKCYEKELGRLLRDAPSGIGSIFLSASELEDGSEEMGQGAVSS SPRELLSNSEQLN
-
Molecular Weight
58 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNL3, a member of the interferon lambda family, plays a crucial role in the innate immune response against viral infections. It is primarily produced by epithelial cells in response to pathogen recognition and has been implicated in the regulation of immune responses, particularly against viruses such as hepatitis C and influenza. Research into IFNL3 has gained momentum due to its potential therapeutic applications in treating viral infections and its association with viral clearance outcomes in infected individuals. Variations in the IFNL3 gene have been linked to differing responses to antiviral therapies, highlighting its significance in personalized medicine. Moreover, studies have indicated that IFNL3 may influence intestinal health and gut microbiota composition, indicating a broader impact on overall immune function. Understanding the mechanisms of IFNL3 production, its signaling pathways, and its interactions with other immune components is vital for developing targeted therapies. Consequently, IFNL3 recombinant proteins are being explored in preclinical and clinical settings to assess their efficacy and safety as potential therapeutics, paving the way for novel strategies in combating viral diseases and enhancing host defense mechanisms. As ongoing research continues to unveil the complexities of IFNL3's role in immune responses, it holds promise for innovative approaches in immunotherapy and personalized treatment regimens.
